Molecular profiling of clear cell adenocarcinoma of the urinary tract

被引:0
作者
Chieh-Yu Lin
Atif Saleem
Henning Stehr
James L. Zehnder
Benjamin A. Pinsky
Christian A. Kunder
机构
[1] Washington University School of Medicine,Department of Pathology and Immunology
[2] Stanford University School of Medicine,Department of Pathology
[3] Stanford University School of Medicine,Department of Medicine, Division of Infectious Diseases and Geographic Medicine
来源
Virchows Archiv | 2019年 / 475卷
关键词
Clear cell adenocarcinoma; Urinary tract; Molecular profiling;
D O I
暂无
中图分类号
学科分类号
摘要
Clear cell adenocarcinoma (CCA) of the urinary tract is a rare type of malignancy whose molecular profiles remain undefined. Here we reported an integrated clinicopathologic and molecular profiling analysis of four cases of clear cell adenocarcinoma arising in the urethra or the bladder. Utilizing a clinically validated 130-gene exon-sequencing assay, we identified recurrent pathogenic PIK3CA (p. E545K) and KRAS (p.G12D) variants in three of four (75%) of the cases. In addition, an APC variant (P.S2310X), a TP53 variant (p.R273C), and a MYC amplification event were identified. The only CCA case without either PIK3CA or KRAS variants has a distinct pathogenesis through BK virus, demonstrated by positive BK virus PCR and SV40 immunohistochemistry. The novel finding of recurrent variants in the PI3K/AKT/mTOR pathway provides not only insights into oncogenesis but also potential clinical therapeutic targets for patients with clear cell adenocarcinoma of the urinary tract.
引用
收藏
页码:727 / 734
页数:7
相关论文
共 224 条
[11]  
Tong GX(2012)Primary clear cell adenocarcinoma of the bladder with recurrence: a case report and literature review World J Surg Oncol 10 33-1456
[12]  
Weeden EM(2015)High-dose-rate brachytherapy - a novel treatment approach for primary clear cell adenocarcinoma of male urethra J Contemp Brachytherapy 7 248-591
[13]  
Hamele-Bena D(1998)Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison Hum Pathol 29 1451-930
[14]  
Huan Y(2014)Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing Am J Pathol 184 584-929
[15]  
Unger P(2017)Calibration of BK virus nucleic acid amplification testing to the 1st WHO international standard for BK virus J Clin Microbiol 55 923-459
[16]  
Memeo L(2013)Frequency of TERT promoter mutations in human cancers Nat Commun 4 2185-291
[17]  
O’Toole K(2005)Oncogenic PI3K deregulates transcription and translation Nat Rev Cancer 5 921-24
[18]  
Herawi M(2006)Mutation of the PIK3CA oncogene in human cancers Br J Cancer 94 455-846
[19]  
Drew PA(2018)Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 15 273-774
[20]  
Pan CC(2015)PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting Nat Rev Cancer 15 7-210